Literature DB >> 35226336

Potential biomarkers in the fibrosis progression of nonalcoholic steatohepatitis (NASH).

Z Wang1, Z Zhao1, Y Xia1, Z Cai1, C Wang1, Y Shen1, R Liu1, H Qin1, J Jia2, G Yuan3.   

Abstract

PURPOSE: Fibrosis is the only histological feature reflecting the severity and prognosis of nonalcoholic steatohepatitis (NASH). We aim to explore novel genes associated with fibrosis progression in NASH.
METHODS: Two human RNA-seq datasets were downloaded from the public database. Weighted gene co-expression network analysis (WGCNA) was used to identify their co-expressed modules and further bioinformatics analysis was performed to identify hub genes within the modules. Finally, based on two single-cell RNA-seq datasets from mice and one microarray dataset from human, we further observed the expression of hub genes in different cell clusters and liver tissues.
RESULTS: 7 hub genes (SPP1, PROM1, SOX9, EPCAM, THY1, CD34 and MCAM) associated with fibrosis progression were identified. Single-cell RNA-seq analysis revealed that those hub genes were expressed by different cell clusters such as cholangiocytes, natural killer (NK) cells, and hepatic stellate cells (HSCs). We also found that SPP1 and CD34 serve as markers of different HSCs clusters, which are associated with inflammatory response and fibrogenesis, respectively. Further study suggested that SPP1, SOX9, MCAM and THY1 might be related to NASH-associated hepatocellular carcinoma (HCC). Receiver operating characteristic (ROC) analysis showed that the high expression of these genes could well predict the occurrence of HCC. At the same time, there were significant differences in metabolism-related pathway changes between different HCC subtypes, and SOX9 may be involved in these changes.
CONCLUSIONS: The present study identified novel genes associated with NASH fibrosis and explored their effects on fibrosis from a single-cell perspective that might provide new ideas for the early diagnosis, monitoring, evaluation, and prediction of fibrosis progression in NASH.
© 2022. Italian Society of Endocrinology (SIE).

Entities:  

Keywords:  Fibrosis; HCC; NASH; Single-cell RNA-seq; WGCNA

Mesh:

Substances:

Year:  2022        PMID: 35226336     DOI: 10.1007/s40618-022-01773-y

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  66 in total

1.  Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study.

Authors:  Eduardo Vilar-Gomez; Luis Calzadilla-Bertot; Vincent Wai-Sun Wong; Marlen Castellanos; Rocio Aller-de la Fuente; Mayada Metwally; Mohammed Eslam; Licet Gonzalez-Fabian; María Alvarez-Quiñones Sanz; Antonio Felix Conde-Martin; Bastiaan De Boer; Duncan McLeod; Anthony Wing Hung Chan; Naga Chalasani; Jacob George; Leon A Adams; Manuel Romero-Gomez
Journal:  Gastroenterology       Date:  2018-05-05       Impact factor: 22.682

2.  Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.

Authors:  Paul Angulo; David E Kleiner; Sanne Dam-Larsen; Leon A Adams; Einar S Bjornsson; Phunchai Charatcharoenwitthaya; Peter R Mills; Jill C Keach; Heather D Lafferty; Alisha Stahler; Svanhildur Haflidadottir; Flemming Bendtsen
Journal:  Gastroenterology       Date:  2015-04-29       Impact factor: 22.682

Review 3.  Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis.

Authors:  Anna M Diehl; Christopher Day
Journal:  N Engl J Med       Date:  2017-11-23       Impact factor: 91.245

Review 4.  Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.

Authors:  Zobair Younossi; Quentin M Anstee; Milena Marietti; Timothy Hardy; Linda Henry; Mohammed Eslam; Jacob George; Elisabetta Bugianesi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-09-20       Impact factor: 46.802

5.  A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.

Authors:  Sven M Francque; Pierre Bedossa; Vlad Ratziu; Quentin M Anstee; Elisabetta Bugianesi; Arun J Sanyal; Rohit Loomba; Stephen A Harrison; Rozalina Balabanska; Lyudmila Mateva; Nicolas Lanthier; Naim Alkhouri; Christophe Moreno; Jörn M Schattenberg; Diana Stefanova-Petrova; Luisa Vonghia; Régine Rouzier; Maeva Guillaume; Alexander Hodge; Manuel Romero-Gómez; Philippe Huot-Marchand; Martine Baudin; Marie-Paule Richard; Jean-Louis Abitbol; Pierre Broqua; Jean-Louis Junien; Manal F Abdelmalek
Journal:  N Engl J Med       Date:  2021-10-21       Impact factor: 91.245

Review 6.  Maladaptive regeneration - the reawakening of developmental pathways in NASH and fibrosis.

Authors:  Changyu Zhu; Ira Tabas; Robert F Schwabe; Utpal B Pajvani
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-10-13       Impact factor: 46.802

Review 7.  Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis.

Authors:  Robert F Schwabe; Ira Tabas; Utpal B Pajvani
Journal:  Gastroenterology       Date:  2020-02-08       Impact factor: 22.682

Review 8.  Nonalcoholic Steatohepatitis: A Review.

Authors:  Adam C Sheka; Oyedele Adeyi; Julie Thompson; Bilal Hameed; Peter A Crawford; Sayeed Ikramuddin
Journal:  JAMA       Date:  2020-03-24       Impact factor: 56.272

9.  Prevalence of hepatic steatosis in patients with type 2 diabetes and response to glucose-lowering treatments. A multicenter retrospective study in Italian specialist care.

Authors:  M L Morieri; N Vitturi; A Avogaro; G Targher; G P Fadini
Journal:  J Endocrinol Invest       Date:  2021-01-11       Impact factor: 4.256

10.  Plasma Bile Acid Profile in Patients with and without Type 2 Diabetes.

Authors:  Alessandro Mantovani; Andrea Dalbeni; Denise Peserico; Filippo Cattazzo; Michele Bevilacqua; Gian Luca Salvagno; Giuseppe Lippi; Giovanni Targher; Elisa Danese; Cristiano Fava
Journal:  Metabolites       Date:  2021-07-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.